Cadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. In March 2014, Mallinckrodt Plc acquired Cadence Pharmaceuticals, Inc. In March 2014, Mallinckrodt Plc completed the acquisition of Cadence Pharmaceuticals.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:CADX
- CUSIP: 12738T10
- Web: N/A
- Trailing P/E Ratio:
- Foreward P/E Ratio: 26.38
- P/E Growth:
Frequently Asked Questions for Cadence Pharmaceuticals (NASDAQ:CADX)
What is Cadence Pharmaceuticals' stock symbol?
Cadence Pharmaceuticals trades on the NASDAQ under the ticker symbol "CADX."
Who are some of Cadence Pharmaceuticals' key competitors?
Some companies that are related to Cadence Pharmaceuticals include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), NMC Health PLC (NMC), Catalent (CTLT), Cotiviti Holdings (COTV), Puma Biotechnology (PBYI), Hikma Pharmaceuticals Plc (HIK) and WuXi PharmaTech (Cayman) (WX).
How do I buy Cadence Pharmaceuticals stock?
Shares of Cadence Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cadence Pharmaceuticals' stock price today?
MarketBeat Community Rating for Cadence Pharmaceuticals (NASDAQ CADX)MarketBeat's community ratings are surveys of what our community members think about Cadence Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cadence Pharmaceuticals stock can currently be purchased for approximately $13.98.
Consensus Ratings for Cadence Pharmaceuticals (NASDAQ:CADX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cadence Pharmaceuticals (NASDAQ:CADX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cadence Pharmaceuticals (NASDAQ:CADX)Earnings History by Quarter for Cadence Pharmaceuticals (NASDAQ CADX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/28/2014||Q413||($0.04)||($0.05)||$32.51 million||$33.30 million||View||N/A|
|11/5/2012||Q312||($0.19)||($0.19)||$14.16 million||$13.90 million||View||N/A|
Earnings Estimates for Cadence Pharmaceuticals (NASDAQ:CADX)
Current Year EPS Consensus Estimate: $0.14 EPS
Next Year EPS Consensus Estimate: $0.53 EPS
Dividend History for Cadence Pharmaceuticals (NASDAQ:CADX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cadence Pharmaceuticals (NASDAQ:CADX)Insider Trades by Quarter for Cadence Pharmaceuticals (NASDAQ:CADX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/17/2013||William Larue||CFO||Sell||8,500||$9.12||$77,520.00|| |
|12/2/2013||Scott Byrd||SVP||Sell||7,812||$9.16||$71,557.92|| |
|11/18/2013||William Larue||CFO||Sell||36,000||$7.30||$262,800.00|| |
|7/22/2013||Hazel M Aker||SVP||Sell||6,507||$7.81||$50,819.67|| |
|7/17/2013||William R Larue||CFO||Sell||9,000||$7.26||$65,340.00|| |
|7/15/2013||Hazel M Aker||SVP||Sell||6,508||$7.34||$47,768.72|| |
|6/27/2013||William R Larue||CFO||Sell||9,000||$7.20||$64,800.00|| |
|6/10/2013||Malcolm Lloyd-Smith||SVP||Sell||4,000||$7.44||$29,760.00|| |
|6/7/2013||Scott A Byrd||SVP||Sell||67,115||$7.53||$505,375.95|| |
|3/12/2013||Parters Vii L P Domain||Major Shareholder||Sell||10,464||$5.36||$56,087.04|| |
|2/14/2013||Parters Vii L P Domain||Major Shareholder||Sell||8,714||$5.00||$43,570.00|| |
|2/1/2013||Parters Vii L P Domain||Major Shareholder||Sell||9,769||$4.85||$47,379.65|| |
Headline Trends for Cadence Pharmaceuticals (NASDAQ:CADX)
Latest Headlines for Cadence Pharmaceuticals (NASDAQ:CADX)
Cadence Pharmaceuticals (CADX) Chart for Friday, July, 21, 2017